U.S. FDA Grants Priority Review for XARELTO to Reduce Secondary Cardiovascular Events in Patients with Acute

Janssen Research & Development, LLC announced today that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application filed on December 29, 2011 for XARELTO^ (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome.